Methods for treating behavioral and psychological symptoms in patients with dementia
Combining pure 5-HT6 receptor antagonists with acetylcholinesterase or NMDA receptor antagonists addresses the limitations of current dementia treatments by enhancing efficacy and minimizing side effects for symptoms like agitation and psychosis in dementia patients.
Patent Information
- Application Number
- JP2024132793
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-12-02
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-06
AI Technical Summary
Current pharmacological treatments for behavioral and psychological symptoms in dementia, such as agitation, aggression, psychosis, and apathy, are limited by modest efficacy and significant side effects, including cognitive decline and safety concerns.
A combination therapy using pure 5-HT6 receptor antagonists, such as maspirdine, with acetylcholinesterase inhibitors like donepezil or NMDA receptor antagonists like memantine, to treat behavioral and psychological symptoms in dementia.
The combination therapy effectively reduces symptoms of agitation, aggression, psychosis, and apathy in dementia patients, with improved therapeutic efficacy and reduced side effects compared to monotherapy.
Smart Images

Figure 2024156953000002 
Figure 2024156953000003 
Figure 2024156953000004
Abstract
Description
[Technical field]
[0001] The present invention provides a method for treating behavioral and psychological symptoms in dementia patients, comprising administering an effective dose of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor or an NMDA receptor antagonist. The present invention also relates to a pharmaceutical combination comprising a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor or an NMDA receptor antagonist, in particular for treating behavioral and psychological symptoms in dementia patients. The present invention further provides the use of said compounds in the manufacture of a medicament, and pharmaceutical compositions comprising said compounds for the treatment of the disorders described herein. [Background technology]
[0002] Decline in thinking, memory, behavior, and ability to perform activities of daily living fall under the broader spectrum of dementia. Alzheimer's disease (AD) dementia is the most common form of dementia. Other major forms include Lewy body dementia (LBD), vascular dementia (VD), Parkinson's disease (PD) dementia, dementia associated with schizophrenia, and frontotemporal dementia (FTD). Although pathologically distinct from each other, they share symptoms in common, and mixed forms often coexist. Behavioral and psychological symptoms are one of the common symptoms found across multiple forms of dementia, and represent a heterogeneous group of noncognitive symptoms and behaviors. Behavioral and psychological symptoms of dementia (BPSD) are also known as neuropsychiatric symptoms. BPSD constitutes a major component of the dementia syndrome, regardless of the subtype of dementia. BPSD affects up to 90% of all dementia subjects throughout the course of the disease and is estimated to be independently associated with poor outcomes, including distress among patients and caregivers, early and long-term institutionalization, medication misuse, and increased healthcare costs. These are clinically relevant as well as cognitive symptoms, as they are strongly correlated with the degree of functional and cognitive impairment. BPSD includes agitation / aggression, abnormal motor behavior, abnormal vocalization, anxiety, elation, dysphoria, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes. Clinical evidence suggests that there is extensive overlap between behaviorally relevant circuits and networks associated with these symptoms. The Neuropsychiatric Inventory (NPI) scale is widely used to assess neuropsychological symptoms in patients with dementia.
[0003] Psychotic symptoms are common across multiple types of dementia, with prevalence rates ranging from 20% to 70%. In addition to occurring in AD patients, psychosis occurs in patients with other dementias of a wide variety of etiologies (J Cell Mol Med 2012; 16:995-1012). Among patients with AD psychosis, an increased incidence of severe psychosis has been reported to be associated with an increased occurrence of delusions and hallucinations in addition to symptoms of agitation / aggression. At present, there are no approved pharmacological treatments for patients with AD psychosis, particularly those experiencing severe psychotic symptoms.
[0004] Agitation / aggression is frequent in dementia patients and is associated with emotional distress for patients and caregivers, risk of institutionalization, and faster disease progression. The items agitation / aggression, abnormal motor behavior, abnormal vocalization, irritability / lability, anxiety, and disinhibition from the NPI may indicate agitation / aggression. At present, there are no approved pharmacological treatments for the treatment of agitation / aggression in dementia patients. Apathy is also common in dementia and is a major cause of caregiver distress. Apathy is characterized by lack of motivation, reduced spontaneity, akinesia, and emotional indifference. At present, there are no approved pharmacological treatments for the treatment of apathy in dementia patients. Depression is also common in the dementia population. Antidepressants are used to cope, but evidence of their usefulness is mixed. A high prevalence of sleep disorders is also seen in dementia patients.
[0005] A combination of non-pharmacological and judicious use of pharmacological interventions is the recommended treatment strategy for managing BPSD. Published literature indicates that modest symptomatic benefits are associated with short-term treatment of patients with BPSD with atypical antipsychotics such as risperidone, olanzapine, and aripiprazole. However, the benefits of longer-term treatment are less clear (N Engl J Med. 2006; 355(15):1525-1538). In addition, this modest benefit must be balanced against significant safety concerns associated with these drugs, especially with longer-term use, including risk of accelerated cognitive decline, stroke, and death. Atypical antipsychotics have been associated with a statistically significant acceleration of cognitive decline in patients with AD. 5-HT, a recently approved antipsychotic for PD-associated psychosis, is a promising treatment option for PD-associated psychosis. 2AThe receptor antagonist pimavanserin showed a statistically significant effect on the Neuropsychiatric Inventory Nursing Home Version (NPI-NH) psychosis scale at 6 weeks, but no effect on agitation in the AD study (The Lancet Neurology, 2018, 17, pp. 213-222; NCT02992132). In the AD study, citalopram (30 mg daily) for agitation showed a significant reduction in agitation in 186 AD patients (JAMA 2014; 311:682-91). Cognitive deterioration and QT interval prolongation were observed in the citalopram-treated group.
[0006] Given the limited efficacy of current therapies, there is an urgent need to identify novel pharmacological mechanisms that can address current limitations such as side effects and cognitive deterioration while treating BPSD.
[0007] WO2015083179 discloses a method for the large-scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate.
[0008] WO2017199071 discloses a combination of a pure 5-HT6 receptor (5-HT6R) antagonist and an acetylcholinesterase inhibitor for the treatment of cognitive disorders.
[0009] WO2017199072 discloses a combination of a pure 5-HT6R antagonist and an NMDA antagonist for the treatment of cognitive disorders.
[0010] WO2019008484 discloses the use of a pure 5-HT6R antagonist, specifically 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharma- ceutically acceptable salt thereof. However, this patent application did not disclose the combination of a 5-HT6R antagonist with an acetylcholinesterase inhibitor for the treatment of behavioral and psychological symptoms in dementia patients.
[0011] 5-HT6R antagonists have shown activity against one of the NPI domains, apathy (WO2017 / 194496). In this patent WO2017 / 194496, there is no information about the potential usefulness against other important domains of NPI. However, although multiple NPI domains are included under a single scale, the causative biological basis for each of these symptoms is different. Those skilled in the art would not assume that if a 5-HT6R antagonist is effective against one domain, it would also show activity against other domains. The effect of donepezil is mainly observed in the NPI domain, namely apathy (Int J Geriatr Psychiatry. 2011 February;26(2):150-7). Furthermore, donepezil has been evaluated for the treatment of agitation / aggression in Alzheimer's disease patients, but donepezil showed no significant efficacy compared to placebo (N Engl J Med. 2007 Oct. 4;357(14):1382-92).
[0012] Memantine, an NMDA receptor antagonist, is expected to work by blocking glutamate in the brain (Neurotox Res (2013) 24:358-369), whereas 5-HT6R antagonists work by increasing glutamate levels in the brain in addition to other mechanisms, including increasing acetylcholine levels (Expert Opin Investig Drugs. 2015;24(12):1515-28). Thus, given these contrasting mechanisms, it is unlikely that the combination of a pure 5-HT6R antagonist and an NMDA receptor antagonist will show consistent or favorable effects in their pharmacological activity in the domain of BPSD.
[0013] Masupirdine (1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole) is a pure 5-HT6R antagonist with high selectivity for closely related serotonin subtypes.
[0014] The present invention provides a pure 5-HT6R antagonist or a pharma- ceutically acceptable salt thereof for treating BPSD in combination with or as an adjunct to an acetylcholinesterase inhibitor or an NMDA receptor antagonist. The present invention is based on the unexpected and surprising discovery that a combination of a pure 5-HT6R antagonist with a compound acting as an acetylcholinesterase inhibitor, such as donepezil, or with the NMDA receptor antagonist memantine, addresses a range of behavioral and psychological symptoms such as agitation / aggression, psychosis (delusions and / or hallucinations), anxiety, apathy, and sleep disorders in dementia patients. Based on these results, it can be inferred that such combined administration and / or co-treatment of a pure 5-HT6R antagonist with an acetylcholinesterase inhibitor or an NMDA receptor antagonist will result in improved therapeutic efficacy in humans. Furthermore, the pure 5-HT6R antagonist maspiridine or a pharma-ceutically acceptable salt thereof of the present invention is more effective in treating BPSD when combined with donepezil or memantine. [Prior art documents] [Patent documents]
[0015] [Patent Document 1] WO2015083179 [Patent Document 2] WO2017199071 [Patent Document 3] WO2017199072 [Patent Document 4] WO2019008484 [Patent Document 5] WO2017 / 194496 [Patent Document 6] U.S. Patent No. 7,875,605 [Patent Document 7] U.S. Patent No. 9,540,321 [Non-patent literature]
[0016]
Non-licensed literature 1
Non-licensed Document 2
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
[0017] The present invention provides a method for the treatment of behavioral and psychological symptoms in dementia patients, comprising administering an effective dose of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor or an NMDA receptor antagonist. [Means for solving the problem]
[0018] In one aspect, the present invention provides a method for the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia, comprising administering an effective dose of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor or an NMDA receptor antagonist.
[0019] In another aspect, the present invention relates to a method for the treatment of behavioral and psychological symptoms in dementia patients, comprising the step of administering an effective dose of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor or an NMDA receptor antagonist, wherein the behavioral and psychological symptoms in dementia are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, or changes in appetite and feeding.
[0020] In another aspect, the present invention relates to a method for the treatment of behavioral and psychological symptoms in dementia patients, comprising administering effective doses of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor or an NMDA receptor antagonist, wherein the pure 5-HT6 receptor antagonist is maspiridine or a pharma- ceutically acceptable salt thereof.
[0021] In another aspect, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering an effective dose of maspiridine or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine, or a pharmaceutically acceptable salt thereof.
[0022] In another aspect, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering an effective dose of maspiridine, or a pharma- ceutical acceptable salt thereof, and the NMDA receptor antagonist memantine, or a pharma- ceutical acceptable salt thereof.
[0023] In another aspect, the present invention relates to the use of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor in the manufacture of a medicament for the treatment of behavioural and psychological symptoms in dementia patients, wherein said pure 5-HT6 receptor antagonist is maspiridine or a pharma- ceutically acceptable salt thereof.
[0024] In another aspect, the present invention relates to the use of maspiridine or a pharma- ceutically acceptable salt thereof and an acetylcholinesterase inhibitor, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of behavioral and psychological symptoms in a dementia patient.
[0025] In another aspect, the present invention relates to the use of maspiridine, or a pharma- ceutical acceptable salt thereof, and the NMDA receptor antagonist memantine, or a pharma- ceutical acceptable salt thereof, in the manufacture of a medicament for the treatment of behavioral and psychological symptoms in a dementia patient.
[0026] In another aspect, the present invention relates to a pharmaceutical composition comprising a pure 5-HT6 receptor antagonist maspirdine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor, wherein said acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine, or a pharma- ceutical acceptable salt thereof, for the treatment of behavioral and psychological symptoms in dementia patients.
[0027] In another aspect, the present invention relates to a pharmaceutical composition comprising a pure 5-HT6 receptor antagonist maspiridine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist memantine or a pharma- ceutical acceptable salt thereof, for the treatment of behavioral and psychological symptoms in dementia patients.
[0028] In another aspect, the present invention relates to a pharmaceutical combination of a pure 5-HT6 receptor antagonist maspirdine or a pharma- ceutically acceptable salt thereof with an acetylcholinesterase inhibitor, wherein said acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine, or a pharma- ceutically acceptable salt thereof, for the treatment of behavioral and psychological symptoms in dementia patients.
[0029] In another aspect, the present invention relates to a pharmaceutical combination of a pure 5-HT6 receptor antagonist, maspiridine, or a pharma- ceutical acceptable salt thereof, and an NMDA receptor antagonist, memantine, or a pharma- ceutical acceptable salt thereof, for the treatment of behavioral and psychological symptoms in dementia patients. [Brief description of the drawings]
[0030] [Figure 1]FIG. 1 shows the effect of the combination of maspirudine and donepezil on aggression levels compared to maspirudine or donepezil alone. [Diagram 2] FIG. 1 shows the effect of the combination of maspiridine and memantine on aggression levels compared to maspiridine or memantine alone. [Diagram 3] FIG. 1 shows the effect of the combination of maspirudine and donepezil on hallucinations compared to maspirudine or donepezil alone. [Figure 4] FIG. 1 shows the effect of a combination of maspiridine and donepezil on dopamine and norepinephrine levels in the prefrontal cortex of male Wistar rats compared to donepezil. [Diagram 5] FIG. 1 shows the effect of a combination of maspiridine and memantine compared to memantine on dopamine and norepinephrine levels in the prefrontal cortex of male Wistar rats. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] Unless otherwise stated, the following terms used in the specification and claims have the following meanings.
[0032] As used herein, the term "5-HT6 receptor antagonist" refers to a ligand or drug that exhibits affinity for the 5-HT6 receptor and blocks or inhibits the function / binding of a 5-HT6 receptor agonist.
[0033] As used herein, the term "pure 5-HT6 receptor antagonist" refers to a 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 2A , 5-HT 2C , 5-HT4, 5-HT 5A It refers to a 5-HT6 receptor antagonist that has extremely high selectivity (>250-fold) over closely related serotonin subtypes such as 5-HT7 and 5-HT6 receptor antagonists.
[0034] An example of a pure 5-HT6 receptor antagonist is (1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole).
[0035] The International Nonproprietary Name (INN) of (1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole) is maspiridine.
[0036] An example of a pharma- ceutically acceptable salt of the above pure 5-HT6 receptor antagonist maspirdine is the dimesylate monohydrate.
[0037] Maspiridine dimesylate monohydrate is also known as SUVN-502, which has the chemical structure displayed below.
[0038] [ka]
[0039] Maspirdine is commonly administered as maspirdine dimesylate monohydrate. The compound maspirdine dimesylate monohydrate and its preparation were described in U.S. Pat. No. 7,875,605, U.S. Pat. No. 9,540,321, and in the article J. Med. Chem. 2017, 60, 5, pp. 1843-1859.
[0040] As used herein, the term "active ingredient" or "active compound" or "compound" refers to a 5-HT6 receptor antagonist or an acetylcholinesterase inhibitor or an NMDA receptor antagonist.Preferably, the 5-HT6 receptor antagonist is (1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole) or a pharmaceutically acceptable salt thereof, the acetylcholinesterase inhibitor is donepezil, rivastigmine, galantamine or a pharmaceutically acceptable salt thereof, and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.
[0041] As used herein, the term "acetylcholinesterase inhibitor" refers to a chemical or drug that inhibits the acetylcholinesterase enzyme from breaking down acetylcholine, thereby increasing the level of the neurotransmitter acetylcholine. Examples of acetylcholinesterase inhibitors are donepezil, rivastigmine, and galantamine. Preferably, the acetylcholinesterase inhibitor is donepezil, rivastigmine, galantamine, or a pharmaceutically acceptable salt thereof.
[0042] Donepezil is a drug approved for the treatment of mild, moderate, and severe dementia due to AD. Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase and is sold as the hydrochloride salt under the trade name Aricept®.
[0043] Rivastigmine is a drug approved for the treatment of mild, moderate, and severe dementia due to AD. Rivastigmine is a reversible cholinesterase inhibitor sold as the tartrate salt under the trade names Exelon® and Exelon Patch®.
[0044] Galantamine is a drug approved for the treatment of mild, moderate, and severe dementia due to AD. Galantamine is a reversible, competitive acetylcholinesterase inhibitor and is sold as the hydrobromide salt under the trade name Razadyne®.
[0045] As used herein, the term "NMDA receptor antagonist" refers to a class of compounds that act on the glutamatergic system by inhibiting the NMDA receptor. An example of an NMDA receptor antagonist is memantine. Memantine is a drug approved for the treatment of moderate to severe dementia due to AD. Memantine is sold as the hydrochloride salt under the trade names Namenda® and Namenda XR®.
[0046] The phrase "effective amount" or "effective dose" is defined as an amount of a compound of the present invention that (i) treats a particular disease, condition, or disorder described herein; (ii) relieves one or more symptoms of a particular disease, condition, or disorder described herein; or (iii) delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.
[0047] As used herein, the term "pharmaceutical acceptable salt" refers to a salt of an active compound prepared by reaction with an appropriate organic or inorganic acid or acid derivative depending on the specific substituents found on the compound described herein. The pharmaceutical acceptable salt includes, but is not limited to, dimesylate, dihydrochloride, oxalate, succinate, tartrate, and the like. Preferably, the pharmaceutical acceptable salt is dihydrochloride and dimesylate. More preferably, the pharmaceutical acceptable salt is dimesylate or hydrochloride.
[0048] As used herein, the term "patient" refers to an animal. Preferably, the term "patient" refers to a mammal. The term mammal includes animals such as mice, rats, dogs, rabbits, pigs, monkeys, elephants, camels, horses, and humans. More preferably, the term "patient" refers to a human.
[0049] The term "behavioral and psychological symptoms", also known as neuropsychiatric symptoms, refers to a heterogeneous group of non-cognitive symptoms and behaviors occurring in people with dementia. BPSD constitutes a major component of the dementia syndrome, regardless of the subtype of dementia. Behavioral and psychological symptoms include domains such as agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, or changes in appetite and feeding. It also refers to any physical or verbal behavior of people with dementia that has the effect of harming or rejecting others, including aggressive behaviors such as hitting, kicking, biting, and screaming.
[0050] As used herein, the term "dementia" includes Alzheimer's disease (AD) dementia, dementia associated with schizophrenia, Parkinson's disease (PD) dementia, Lewy body dementia (LBD), vascular dementia, and frontotemporal dementia (FTD).
[0051] As used herein, the term "agitation / aggression" refers to "agitation and / or aggression."
[0052] As used herein, the term "delusions and / or hallucinations" refers to "delusions or hallucinations, or delusions and hallucinations."
[0053] As used herein, the term "Alzheimer's disease" refers to dementia that leads to problems with memory, thinking, and behavior. Alzheimer's disease can be mild, moderate, or severe.
[0054] As used herein, the terms "treatment" or "treating" refer to any treatment of a disease in a mammal, including (a) delaying or preventing the onset of clinical symptoms, and / or (b) causing regression of clinical symptoms.
[0055] As used herein, the term "compound for use" encompasses any one or more of the following: (1) use of a compound; (2) method of use of a compound; (3) use in therapy; (4) use for the manufacture of a pharmaceutical composition / medicine for treatment / treating; or (5) method of treatment / treating / preventing / alleviating / inhibiting comprising administering an effective amount of said active compound to a patient in need thereof.
[0056] Embodiment Although the present invention encompasses all examples described herein without being limited thereto, preferred aspects and elements of the present invention are discussed herein in the form of the following embodiments.
[0057] In one embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor.
[0058] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist.
[0059] In some embodiments, the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
[0060] In some embodiments, the behavioral and psychological symptoms in dementia patients are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0061] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in an Alzheimer's disease dementia patient, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor.
[0062] In another embodiment, the present invention relates to a method for treating behavioral and psychological symptoms in a patient with dementia associated with schizophrenia, comprising administering an effective dose of maspiridine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor.
[0063] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a Parkinson's disease dementia patient, comprising administering an effective dose of maspiridine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor.
[0064] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a patient with dementia with Lewy bodies, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor.
[0065] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a patient with vascular dementia, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor.
[0066] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a patient with frontotemporal dementia, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an acetylcholinesterase inhibitor.
[0067] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in an Alzheimer's disease dementia patient, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist.
[0068] In another embodiment, the present invention relates to a method for treating behavioral and psychological symptoms in a patient with dementia associated with schizophrenia, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist.
[0069] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a Parkinson's disease dementia patient, comprising administering an effective dose of maspiridine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist.
[0070] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a patient with dementia with Lewy bodies, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist.
[0071] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a patient with vascular dementia, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist.
[0072] In another embodiment, the present invention relates to a method for treating behavioral and psychological symptoms in a patient with frontotemporal dementia, comprising administering an effective dose of maspirudine or a pharma- ceutical acceptable salt thereof and an NMDA receptor antagonist.
[0073] In some embodiments, the behavioral and psychological symptoms in Alzheimer's disease dementia patients are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0074] In some embodiments, the behavioral and psychological symptoms in patients with dementia associated with schizophrenia are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0075] In some embodiments, the behavioral and psychological symptoms in Parkinson's disease dementia patients are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0076] In some embodiments, the behavioral and psychological symptoms in patients with Dementia with Lewy Bodies are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0077] In some embodiments, the behavioral and psychological symptoms in patients with vascular dementia are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0078] In some embodiments, the behavioral and psychological symptoms in patients with frontotemporal dementia are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, delusions, hallucinations, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0079] In embodiments, the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine, or a pharma- ceutically acceptable salt thereof.
[0080] In embodiments, the NMDA receptor antagonist is memantine or a pharma- ceutically acceptable salt thereof.
[0081] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering effective doses of maspirudine or a pharma- ceutical acceptable salt thereof and donepezil or a pharma-ceutical acceptable salt thereof.
[0082] In another embodiment, the present invention relates to a method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering effective doses of maspirudine, or a pharma- ceutically acceptable salt thereof, and memantine, or a pharma- ceutically acceptable salt thereof.
[0083] In some embodiments, the pharma- ceutically acceptable salt of maspirdine is selected from mesylate, hydrochloride, oxalate, succinate, and tartrate salts.
[0084] In certain embodiments, the pharma- ceutically acceptable salt of maspirdine is the dimesylate monohydrate.
[0085] In embodiments, the pharma- ceutically acceptable salt of donepezil is donepezil hydrochloride.
[0086] In embodiments, the pharma- ceutically acceptable salt of memantine is memantine hydrochloride.
[0087] In a preferred embodiment, the behavioral / psychological symptom in a dementia patient is agitation / aggression.
[0088] In a preferred embodiment, the behavioral and psychological symptoms in a dementia patient are delusions and / or hallucinations.
[0089] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is delusions.
[0090] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is hallucinations.
[0091] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is alterations in sleep and nighttime behavior.
[0092] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is a change in appetite and feeding.
[0093] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is abnormal motor behavior.
[0094] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is abnormal vocalizations.
[0095] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is irritability.
[0096] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is apathy.
[0097] In a preferred embodiment, the behavioral / psychological symptom in a dementia patient is depression / dysphoria.
[0098] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is disinhibition.
[0099] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is mood elevation / euphoria.
[0100] In a preferred embodiment, the behavioral and psychological symptom in a dementia patient is anxiety.
[0101] In a preferred embodiment, the behavioral / psychological symptom in an Alzheimer's disease dementia patient is agitation / aggression.
[0102] In a preferred embodiment, the behavioral and psychological symptoms in an Alzheimer's disease dementia patient are delusions and / or hallucinations.
[0103] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is delusions.
[0104] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is hallucinations.
[0105] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is alterations in sleep and nighttime behavior.
[0106] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is a change in appetite and feeding.
[0107] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is abnormal motor behavior.
[0108] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is abnormal vocalizations.
[0109] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is irritability.
[0110] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is apathy.
[0111] In a preferred embodiment, the behavioral / psychological symptom in an Alzheimer's disease dementia patient is depression / dysphoria.
[0112] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is disinhibition.
[0113] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is mood elevation / euphoria.
[0114] In a preferred embodiment, the behavioral and psychological symptom in an Alzheimer's disease dementia patient is anxiety.
[0115] In another embodiment, the present invention relates to a method for the treatment of agitation / aggression in Alzheimer's disease dementia patients, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0116] In another embodiment, the present invention relates to a method for the treatment of delusions and / or hallucinations in a patient with Alzheimer's disease dementia, comprising administering an effective dose of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0117] In another embodiment, the present invention relates to a method for the treatment of delusions in an Alzheimer's disease dementia patient, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0118] In another embodiment, the present invention relates to a method for the treatment of hallucinations in a patient with Alzheimer's disease dementia, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0119] In another embodiment, the present invention relates to a method for the treatment of altered sleep and nighttime behavior in patients with Alzheimer's disease dementia, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0120] In another embodiment, the present invention relates to a method for the treatment of appetite and feeding changes in Alzheimer's disease dementia patients, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0121] In another embodiment, the present invention relates to a method for the treatment of abnormal motor behavior in Alzheimer's disease dementia patients, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0122] In another embodiment, the present invention relates to a method for the treatment of abnormal vocalizations in Alzheimer's disease dementia patients, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0123] In another embodiment, the present invention relates to a method for the treatment of anxiety in an Alzheimer's disease dementia patient, comprising administering an effective dose of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0124] In another embodiment, the present invention relates to a method for the treatment of irritability in an Alzheimer's disease dementia patient, comprising administering effective doses of maspirdine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0125] In another embodiment, the present invention relates to a method for the treatment of apathy in Alzheimer's disease dementia patients, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0126] In another embodiment, the present invention relates to a method for the treatment of depression / dysphoria in Alzheimer's disease dementia patients comprising administering effective doses of maspirdine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0127] In another embodiment, the present invention relates to a method for the treatment of disinhibition in a patient with Alzheimer's disease dementia, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0128] In another embodiment, the present invention relates to a method for the treatment of mood elevation / euphoria in Alzheimer's disease dementia patients comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0129] In another embodiment, the present invention relates to a method for the treatment of anxiety in an Alzheimer's disease dementia patient, comprising administering an effective dose of maspiridine dimesylate monohydrate and donepezil hydrochloride or memantine hydrochloride.
[0130] In another embodiment, the present invention relates to the use of a pure 5-HT6 receptor antagonist, maspirdine or a pharma- ceutically acceptable salt, and an acetylcholinesterase inhibitor as described above in the manufacture of a medicament for the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia, wherein said behavioral and psychological symptoms are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0131] In another embodiment, the present invention relates to the use of a pure 5-HT6 receptor antagonist, maspirdine or a pharma- ceutically acceptable salt, and an NMDA receptor antagonist as described above in the manufacture of a medicament for the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia, wherein said behavioral and psychological symptoms are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, delusions, hallucinations, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0132] In several embodiments of the present invention, the pure 5-HT6 receptor antagonist and the acetylcholinesterase inhibitor or NMDA receptor antagonist as described above may be administered to a patient simultaneously, separately or sequentially.
[0133] In several embodiments of the present invention, a pure 5-HT6 receptor antagonist as described above may be administered to a patient in combination with an acetylcholinesterase inhibitor or an NMDA receptor antagonist, or as an adjunct to an acetylcholinesterase inhibitor or an NMDA receptor antagonist.
[0134] In another embodiment, the present invention relates to a pharmaceutical combination of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor, wherein said pure 5-HT6 receptor antagonist is maspiridine or a pharmaceutically acceptable salt thereof, and said acetylcholinesterase inhibitor is donepezil, rivastigmine, and galantamine, or a pharmaceutically acceptable salt thereof.
[0135] In another embodiment, the present invention relates to a pharmaceutical combination of a 5-HT6 receptor antagonist and an NMDA receptor antagonist, wherein the pure 5-HT6 receptor antagonist is maspiridine or a pharma- ceutical acceptable salt thereof, and the NMDA receptor antagonist is memantine or a pharma- ceutical acceptable salt thereof.
[0136] In another aspect, the invention relates to a pharmaceutical combination comprising maspirdine dimesylate monohydrate and donepezil hydrochloride.
[0137] In another aspect, the invention relates to a pharmaceutical combination comprising maspirdine dimesylate monohydrate and memantine hydrochloride.
[0138] In another embodiment, the present invention relates to said pharmaceutical combination for the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia, wherein said behavioral and psychological symptoms are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
[0139] In another embodiment, the present invention relates to said pharmaceutical combination for the treatment of agitation / aggression in Alzheimer's disease dementia patients.
[0140] In another embodiment, the present invention relates to said pharmaceutical combination for the treatment of delusions and / or hallucinations in Alzheimer's disease dementia patients.
[0141] In yet another embodiment, the active ingredients of the present invention may be administered by all possible routes of administration.
[0142] In yet another embodiment, the active ingredients of the present invention may be administered by oral, nasal, topical, or parenteral routes.
[0143] In yet another embodiment, the active ingredients of the present invention can be administered by the same or different routes of administration. For example, the 5-HT6 receptor antagonist of the present invention can be administered orally, and the acetylcholinesterase inhibitor or NMDA receptor antagonist can be administered transdermally.
[0144] In yet another embodiment, the active ingredients of the present invention are typically administered by formulating the active ingredient into a pharmaceutical composition in accordance with standard pharmaceutical practice.
[0145] The pharmaceutical compositions of the present invention may be formulated in a conventional manner using one or more pharma- ceutically acceptable excipients, such as diluents, disintegrants, binders, lubricants, glidants, polymers, coating agents, solvents, cosolvents, preservatives, wetting agents, thickeners, antifoaming agents, sweeteners, flavorings, antioxidants, colorants, solubilizers, plasticizers, dispersing agents, and the like. The excipients are selected from microcrystalline cellulose, mannitol, lactose, pregelatinized starch, sodium starch glycolate, corn starch or derivatives thereof, povidone, crospovidone, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, talc, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, zinc stearate, stearic acid or hydrogenated vegetable oils, gum arabic, magnesium oxide, glucose, fats, waxes, natural or hydrogenated oils, water, saline or alcohol, e.g. ethanol, propanol or glycerol, sugar solutions such as glucose or mannitol solutions, etc., or mixtures of the various excipients.
[0146] In yet another embodiment, the active ingredients of the present invention may be formulated in the form of pills, tablets, coated tablets, capsules, powders, granules, pellets, patches, implants, films, semisolids, liquids, gels, aerosols, emulsions, elixirs, etc. Such pharmaceutical compositions and processes for preparing the same are well known in the art.
[0147] In yet another embodiment, the pharmaceutical composition of the present invention contains the active compound of the present invention or a pharma- ceutical acceptable salt thereof in an amount of 1-90%, 5-75%, or 10-60% by mass. The amount of the active compound or a pharma- ceutical acceptable salt thereof in the pharmaceutical composition may be in the range of about 1 mg to about 500 mg, about 5 mg to about 400 mg, about 5 mg to about 250 mg, or about 7 mg to about 150 mg, or any range included within the broader range of 1 mg to 500 mg.
[0148] In yet another embodiment, the pharmaceutical compositions of the present invention may be in conventional formulations such as immediate release formulations, modified release formulations such as sustained release, delayed release, and extended release formulations, or novel delivery systems such as orally disintegrating formulations and transdermal patches.
[0149] The dosage of the active compound may vary depending on factors such as the age and weight of the patient, the nature, the route of administration, and the severity of the disease to be treated, as well as other such factors.
[0150] In yet another embodiment, the 5-HT6 receptor antagonist maspiridine or a pharma- ceutically acceptable salt thereof may be administered in combination with an acetylcholinesterase inhibitor or an NMDA receptor antagonist in a daily dose of 25 mg to 125 mg, such as 25, 30, 50, 75, 100, or 125, preferably in a daily dose of 25, 30, 50, 75, 100, or 125 mg, and most preferably in a daily dose of 10, 25, 50, 75, 100, or 125 mg.
[0151] In yet another embodiment, the acetylcholinesterase inhibitor may be administered in combination with the 5-HT6 receptor antagonist in a daily dose of 5 mg to 30 mg; 5, 6, 8, 9.5, 10, 12, 13, 13.3, 15, 16, 23, 24, 25, or 30 mg, preferably in a daily dose of 5, 6, 8, 9.5, 10, 12, 13, 13.3, 16, 23, 24, or 25 mg, most preferably in a daily dose of 5, 6, 8, 9.5, 10, 12, 13.3, 16, 23, or 24 mg.
[0152] In yet another embodiment, the acetylcholinesterase inhibitor donepezil may be administered in combination with the 5-HT6 receptor antagonist in a daily dose of 5 mg to 30 mg, such as 5, 10, 15, 23, 25, or 30 mg, preferably in a daily dose of 5, 10, 23, or 25 mg, most preferably in a daily dose of 5, 10, or 23 mg.
[0153] In yet another embodiment, the NMDA receptor antagonist memantine may be administered in combination with the 5-HT6 receptor antagonist in a daily dose of 5 mg to 40 mg, such as 5, 7, 10, 14, 20, 21, 28, or 40 mg, preferably 5, 7, 10, 14, 21, or 28 mg.
[0154] In yet another embodiment, the treatment comprises administering to the patient between 25 mg and 125 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
[0155] In yet another embodiment, the treatment comprises administering to the patient 50 mg to 100 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
[0156] In yet another embodiment, the treatment comprises administering to the patient 25 mg to 50 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
[0157] In yet another embodiment, the treatment comprises administering to the patient between 75 mg and 100 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
[0158] In yet another embodiment, the treatment comprises administering to the patient between 25 mg and 75 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
[0159] In yet another embodiment, the treatment comprises administering to the patient between 75 mg and 125 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
[0160] In yet another embodiment, the treatment comprises administering to the patient between 5 mg and 25 mg of donepezil or a pharma- ceutically acceptable salt thereof per day.
[0161] In yet another embodiment, the treatment comprises administering to the patient 5 mg, 10 mg, or 23 mg of donepezil or a pharma- ceutically acceptable salt thereof per day.
[0162] In yet another embodiment, the treatment comprises administering to the patient between 5 mg and 30 mg of memantine or a pharma- ceutically acceptable salt thereof per day.
[0163] In yet another embodiment, the treatment comprises administering to the patient between 5 mg and 25 mg of memantine or a pharma- ceutically acceptable salt thereof per day.
[0164] In yet another embodiment, the treatment comprises administering to the patient 5 mg, 7 mg, 14 mg, 10 mg, 21 mg, 25 mg, 28 mg, or 30 mg of memantine or a pharma- ceutically acceptable salt thereof per day.
[0165] In yet another embodiment, the treatment comprises administering to the patient the 5-HT6 receptor antagonist maspiridine or a pharma- ceutically acceptable salt thereof and an acetylcholinesterase inhibitor or an NMDA receptor antagonist 1-3 times per day, 1-3 times per week, or 1-3 times per month. Preferably, the treatment comprises administering to the patient the compounds once per day, twice per day, or three times per day. More preferably, the treatment comprises administering to the patient the compounds once per day or twice per day. EXAMPLES
[0166] Short description: 5-HT 1A :5-hydroxytryptamine 1A receptor 5-HT 1B :5-hydroxytryptamine 1B receptor 5-HT 1D :5-hydroxytryptamine 1D receptor 5-HT 2A :5-hydroxytryptamine 2A receptor 5-HT 2C :5-hydroxytryptamine 2C receptor 5-HT4: 5-hydroxytryptamine 4 receptor 5-HT 5A :5-hydroxytryptamine 5A receptor 5-HT6: 5-hydroxytryptamine 6 receptor 5-HT7: 5-hydroxytryptamine 7 receptor cAMP: cyclic adenosine monophosphate CaCl2: Calcium chloride DOI: 2,5-dimethoxy-4-iodoamphetamine EC 50 : Half maximum effective concentration EDTA: Ethylenediaminetetraacetic acid GPCR: G protein-coupled receptor g: grams HCl: Hydrochloric acid h: time ip: intraperitoneal K b : binding constant K i : Inhibition constant kg: kilogram KCl: Potassium chloride LC-MS / MS: Liquid chromatography / tandem mass spectrometry MgCl2: Magnesium chloride mg: milligram min:minutes MgCl2: Magnesium chloride nM: nanomolar po: oral μM: micromolar μL: microliter mmol or mM: millimolar NaCl: Sodium chloride sc: subcutaneous
[0167] Example 1 K at the 5-HT6 receptor b Value measurements: A stable CHO cell line expressing recombinant human 5-HT6 receptor and pCRE-Luc reporter system was used for the cell-based assay. This assay provides a non-radioactive method to measure the binding of compounds to GPCRs. This particular assay measures the level of intracellular cAMP, which is regulated by the activation or inhibition of the receptor. The recombinant cells carry a luciferase reporter gene under the control of a cAMP response element.
[0168] The cells were grown in Hams F12 medium containing 10% fetal bovine serum (FBS) in 96-well clear bottom white plates. Cells were serum starved overnight before adding compounds or standard agonists. Increasing concentrations of test compounds were added to the cells along with 10 μM serotonin in OptiMEM medium. Incubation continued for 4 hours at 37° C. in a CO2 incubator. Medium was removed and cells were washed with phosphate buffered saline. The cells were lysed and luciferase activity was measured in a luminometer. Luminescence was plotted against the compound concentration using GraphPad Prism software. The EC 50 The K value was defined as the concentration required to reduce luciferase activity by 50%. b Values indicate the concentration of agonist used in the assay and its EC 50 The values were calculated by entering them into the same software. References: Molecular Brain Research, 2001, 90, pp. 110-117 and British Journal of Pharmacology, 2006, 148, pp. 1133-1143.
[0169] Maspirudine exhibits no detectable agonistic activity and antagonistic activity against human recombinant 5-HT6 receptors in a CRE-Luc-based reporter gene assay. b The value is 4.2±0.9 nM.
[0170] Example 2 K at the 5-HT6 receptor i Measurement of values Compounds were tested at MDS pharma services and Novascreen according to the following procedure. Materials and Methods: Receptor source: Human recombinant 5-HT6 receptor expressed in HeLa cells Radioligand: 3H]-LSD (60-80 Ci / mmol) Final ligand concentration - [1.5nM] Non-specific ligand: 5 μM serotonin (5-HT) Reference compound: Methiothepin mesylate Positive control: methiothepin mesylate Incubation conditions: 50 mM Tris-HCl (pH 7.4) containing 10 mM MgCl2, 0.5 mM EDTA, 37°C for 60 min. The reaction was terminated by rapid vacuum filtration onto glass fiber filters. The radioactivity trapped on the filters was measured and compared to the control value to confirm any interaction of the test compound with the cloned serotonin 5-HT6 binding site. Reference: Molecular Pharmacology, 1993, 43, pp. 320-327.
[0171] Maspirudine selectively binds to the 5-HT6 receptor as tested by in vitro radioligand binding techniques to human recombinant 5-HT6 receptors. The K i The value is 2.04nM.
[0172] Example 3 5-HT 2A K at the receptor i Measurement of values The compounds were tested according to the following procedure. Materials and Methods: Receptor source: recombinant mammalian cells Radioligand: 3 H]-Ketanserin (47.3Ci / mmol) Final ligand concentration - [1.75nM] Non-specific ligand: 0.1 mM 1-naphthylpiperazine (1-NP) Reference compound: 1-naphthylpiperazine (1-NP) Positive control: 1-naphthylpiperazine (1-NP) Incubation conditions: The reaction was carried out in 67 mM Tris-HCl (pH 7.4) at 37° C. for 1 hour. The reaction was terminated by rapid vacuum filtration onto a glass fiber filter. The radioactivity trapped on the filter was measured, and the cloned serotonin 5-HT 2A Comparison with the control values was made to identify any interactions with the binding site. Reference: Methods in Molecular Biology, 2002, 190, pp. 31-49
[0173] Human Recombinant 5-HT 2A When tested by in-vitro radioligand binding techniques at the 5-HT receptor, maspiridine 2A It binds weakly to the receptor. K i The value is 2514±377 nM.
[0174] Example 4 Maspiridine was shown to be effective in inhibiting 5-HT1 activation in Novascreen's commercial panel. 1A , 5-HT 1B , 5-HT 1D , 5-HT 2A , 5-HT 2C , 5-HT4, 5-HT 5A It was also evaluated for its 5-HT6 receptor selectivity versus closely related serotonin subtypes such as 5-HT7.
[0175] Maspiridine demonstrated greater than 250-fold selectivity across these receptor subtypes.
[0176] Example 5 Resident-Intruder Task Testing Procedure: Male Swiss albino mice with body weights ranging from 30-40 g (residents) and 15-25 g (intruders) were used. Resident mice were habituated individually in each cage with ovariectomized female mice for at least 2 weeks, and intruder mice were socially habituated for at least 5 days. During habituation, β-estradiol was administered subcutaneously to ovariectomized female mice at a dose of 0.2 mg / kg. After 3 weeks of habituation, intruder mice were exposed to resident mice in the resident animals' home cages for a 10-min period, and the duration of aggression was recorded for 2 days (days 1 and 2). During this 10-min exposure period, ovariectomized female mice were removed from the resident cage, and resident animals were randomized based on the duration of aggression. On day 4 (from first exposure), treatments were administered to each resident animal. Maspiridine (0.30 mg / kg, orally) was administered 60 min before testing, and donepezil (0.30 mg / kg, intraperitoneally) or memantine (0.30 mg / kg, intraperitoneally) was administered 30 min before testing. After a period of rest following administration, resident mice were exposed to the same intruder mouse for 10 min, and the duration of the attack was recorded. Data were analyzed using GraphPad Prism software.
[0177] Findings: The vehicle treated group showed comparable duration of attack when compared to their baseline. The group treated with maspiridine (0.30 mg / kg, oral) alone showed comparable duration of attack when compared to their baseline. The groups treated with donepezil (0.30 mg / kg, intraperitoneally) or memantine (0.30 mg / kg, intraperitoneally) alone showed a reduction in duration of attack when compared to their baseline, but this was not statistically significant. The groups treated with the combination of maspiridine and donepezil or memantine showed a significant reduction in duration of attack (p<0.01) when compared to their baseline, demonstrating a synergistic effect when administered in combination (Figures 1 and 2).
[0178] Conclusion: In a resident-intruder task in Swiss albino mice, the anti-aggression-like activity of maspiridine in combination with donepezil or memantine was better than each treatment alone.
[0179] Example 6 Head shaking reaction Testing Procedure: DOI-induced head-shaking response is considered to be a behavioral model of hallucinations (Pharmacol Rep. 2012;64(6):1567-72). Male Wistar rats, weighing 200–290 g, were weighed and randomized according to their weight. On day 1, rats were first allowed to habituate to the arena for 15 min. On day 2, maspiridine was administered 1 h before testing. Donepezil was administered 30 min before testing. Rats were allowed to habituate 15 min before testing, and DOI was administered subcutaneously at 5 mg / kg immediately after habituation. Rats were then placed in the testing arena, and head-shaking was recorded for 10 min. Data were analyzed using GraphPad Prism software.
[0180] Findings: Rats treated with DOI (5 mg / kg, subcutaneously) showed increased head shaking compared to vehicle-treated rats. Maspiridine significantly reduced the number of head shakings at a dose of 1 mg / kg orally. Maspiridine in combination with donepezil significantly reduced the number of head shakings compared to standard treatment (donepezil) (Figure 3).
[0181] Conclusion: Maspiridine in combination with donepezil can reduce visual hallucinations.
[0182] Example 7 Regulation of intracortical norepinephrine and dopamine levels Testing Procedure: Microdialysis guide cannulas were stereotaxically implanted into the prefrontal cortex (PFC; AP: +3.2 mm, ML: -0.5 mm, DV: -1.0 mm) of male Wistar rats (body weight 240-300 g) under isoflurane anesthesia. Coordinates were taken according to the rat brain atlas (Paxinos and Watson 2004) with reference points taken from the bregma and perpendicular to the skull. Rats were allowed to recover individually for 4 days in round-bottom plexiglass bowls with free access to food and water.
[0183] Sixteen hours before the start of the study, a pre-equilibrated microdialysis probe (4 mm dialysis membrane) was inserted into the PFC through the guide cannula. On the day of the study, the probe was perfused with artificial cerebrospinal fluid (aCSF; NaCl 150 mmol, KCl 3.0 mmol, MgCl 2 0.9 mmol, CaCl 2.2H 2 O 1.7 mmol, pH 6.2) at a flow rate of 1.5 μL / min, followed by a 2-hour stabilization period. Four basal samples were collected at 30-minute intervals before treatment with maspiridine (3 mg / kg, p.o.) or vehicle. Donepezil (1 mg / kg, sc) or memantine (1 mg / kg, sc) or vehicle was administered 30 minutes after administration of maspiridine. After treatment with maspiridine (3 mg / kg, p.o.), dialysate samples were collected for an additional 4-hour period. Dialysates were stored below −50° C. before analysis.
[0184] Norepinephrine and dopamine levels were quantified in the dialysate using an LC-MS / MS method.
[0185] Area under the curve (AUC) values for the percentage change in neurotransmitter levels were calculated and statistical significance between the mean AUC values after combination treatment versus donepezil treatment was compared using Student's unpaired t-test. Statistical significance was determined at p values <0.05.
[0186] Findings: Treatment with donepezil (1 mg / kg, subcutaneous) resulted in an increase in cortical norepinephrine levels with an AUC value of 333.77±39.77, whereas the combination of maspiridine (3 mg / kg, oral) and donepezil (1 mg / kg, subcutaneous) resulted in a significantly higher AUC (590.6±53.01) compared to donepezil alone. These results indicate that the combination resulted in an approximately 77% higher increase in cortical norepinephrine levels (FIG. 4).
[0187] Similarly, treatment with donepezil (1 mg / kg, subcutaneous) resulted in an increase in cortical dopamine levels with an AUC value of 307.79±52.22, whereas the combination of maspiridine (3 mg / kg, oral) and donepezil (1 mg / kg, subcutaneous) resulted in a significantly higher AUC (732.12±124.42) compared to donepezil alone. Results from this study show that the combination resulted in an approximately 138% higher increase in cortical dopamine levels (FIG. 4).
[0188] Treatment with memantine (1 mg / kg, subcutaneous) resulted in an increase in cortical norepinephrine levels with an AUC value of 371.34±22.45, whereas the combination of maspiridine (3 mg / kg, oral) and memantine (1 mg / kg, subcutaneous) resulted in a significantly higher AUC value (539.31±69.12) compared to memantine alone. These results indicate that the combination resulted in an approximately 45% higher increase in cortical norepinephrine levels (FIG. 5).
[0189] Similarly, treatment with memantine (1 mg / kg, subcutaneous) resulted in an increase in cortical dopamine levels with an AUC value of 327.75±24.99, whereas the combination of maspiridine (3 mg / kg, oral) and memantine (1 mg / kg, subcutaneous) resulted in a significantly higher AUC value (587.31±32.47) compared to memantine alone. Results from this study show that the combination resulted in an approximately 79% higher increase in cortical dopamine levels (FIG. 5).
[0190] Conclusion: Cortical norepinephrine and dopamine levels play an important role in managing neuropsychiatric disorders. Maspiridine potentiates the effects of donepezil or memantine on the cortical levels of these neurotransmitters, suggesting that the combination of maspiridine with donepezil or memantine may have potential in the treatment of behavioral and psychiatric disorders.
Claims
1. 1. A method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering an effective dose of maspiridine or a pharmaceutically acceptable salt thereof and an acetylcholinesterase inhibitor or an NMDA receptor antagonist, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine, or a pharmaceutically acceptable salt thereof, or the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.
2. 2. The method of claim 1, wherein the pharma- ceutically acceptable salt of maspiridine is the dimesylate monohydrate.
3. 2. The method of claim 1, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.
4. 2. The method of claim 1, wherein the NMDA receptor antagonist is memantine hydrochloride.
5. 1. A method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering effective doses of maspiridine dimesylate monohydrate and donepezil hydrochloride.
6. 1. A method for the treatment of behavioral and psychological symptoms in a dementia patient, comprising administering effective doses of maspiridine dimesylate monohydrate and memantine hydrochloride.
7. 7. The method of any one of claims 1 to 6, wherein the behavioral and psychological symptoms in dementia patients are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
8. 8. The method of any one of claims 1 to 7, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
9. 2. The method of claim 1, wherein the dementia is Alzheimer's disease dementia, and the behavioral and psychological symptoms in patients with Alzheimer's disease dementia are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
10. 2. The method of claim 1, wherein the dementia is Parkinson's disease dementia and the behavioral and psychological symptoms in Parkinson's disease dementia patients are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
11. 10. The method of claim 1, wherein the treatment comprises administering to the patient 25 mg to 125 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
12. 10. The method of claim 1, wherein the treatment comprises administering to the patient 25 mg to 75 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
13. 10. The method of claim 1, wherein the treatment comprises administering to the patient 75 mg to 125 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
14. 10. The method of claim 1, wherein the treatment comprises administering to the patient 50 mg to 100 mg of maspirudine or a pharma- ceutically acceptable salt thereof per day.
15. 10. The method of claim 1, wherein the treatment comprises administering to the patient 5 mg to 25 mg of donepezil or a pharma- ceutically acceptable salt thereof per day.
16. 10. The method of claim 1, wherein the treatment comprises administering to the patient between 5 mg and 30 mg of memantine or a pharma- ceutically acceptable salt thereof per day.
17. 10. A pharmaceutical composition for the treatment of behavioral and psychological symptoms in dementia patients comprising an effective amount of maspiridine or a pharma- ceutically acceptable salt thereof as defined in claim 1 and an acetylcholinesterase inhibitor or an NMDA receptor antagonist.
18. 18. The pharmaceutical composition of claim 17, wherein the behavioral and psychological symptoms in dementia patients are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalizations, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
19. 18. The pharmaceutical composition of claim 17, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
20. 18. The pharmaceutical composition according to claim 17, wherein the dementia is Alzheimer's disease dementia, and the behavioral and psychological symptoms in patients with Alzheimer's disease dementia are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalization, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
21. 18. The pharmaceutical composition according to claim 17, wherein the dementia is Parkinson's disease dementia, and the behavioral and psychological symptoms in patients with Parkinson's disease dementia are selected from agitation / aggression, delusions and / or hallucinations, abnormal motor behavior, abnormal vocalization, anxiety, elation / euphoria, irritability, depression / dysphoria, apathy, disinhibition, changes in sleep and nocturnal behavior, and changes in appetite and feeding.
22. 18. The pharmaceutical composition of claim 17, which is administered to a patient by oral, nasal, topical, or parenteral route.
23. 18. The pharmaceutical composition of claim 17, which is administered to a patient 1 to 3 times per day, 1 to 3 times per week, or 1 to 3 times per month.
Citation Information
Patent Citations
AMA2014
N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
US7875605B2
Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
US9540321B2
Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
WO2015083179A1
5HT6 receptor antagonists for use in the treatment of alzheimer's disease with apathy as comorbidity
WO2017194496A1
